Experimental triple attack on Tough-to-Treat cancers
NCT ID NCT06320405
Summary
This early-stage trial is testing whether combining three different cancer drugs is safe and effective for patients with advanced solid tumors that have spread or returned after standard treatments. The combination includes two immunotherapy drugs that help the immune system fight cancer and one chemotherapy drug that directly kills cancer cells. Researchers will enroll about 38 adults whose cancers have progressed despite previous therapies to determine the best dose and see if this approach can control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.